Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis.

OBJECTIVE To investigate adult heights attained by patients with 21-hydroxylase deficiency and to perform a meta-analysis of height outcomes reported in this population. STUDY DESIGN A retrospective chart review of our patients >5 years of age (n = 65) who were followed up from 1978 to 1998 for 21-hydroxylase deficiency was conducted. Final height (FH) SD scores and target height (TH) SD scores were determined. The impact of sex, time of diagnosis, and compliance was assessed. Meta-analysis of results from 18 studies was performed; TH was available for 204 of 561 patients. RESULTS Mean FH SD score-TH SD score for our 65 patients was -1.03. For the meta-analysis, mean weighted FH SD score for all 561 patients was -1.37, whereas weighted mean FH SD score-TH SD score for the 204 patients for whom TH was available was -1.21. No difference in outcome was seen for males compared with females, although a statistically significant difference was seen for patients identified early versus late. CONCLUSIONS Adult height in patients with 21-hydroxylase deficiency is often within 1 SD of TH. Early diagnosis and good compliance appear to improve the outcome. Rather than pursuing alternate therapies for congenital adrenal hyperplasia, efforts may instead be focused on early detection and improved compliance with traditional medical therapy.

[1]  W. Greulich,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1999 .

[2]  S. Rivkees,et al.  Home monitoring of 17 hydroxyprogesterone levels in congenitx127drenal hyperplasia with filter paper blood samples. , 1999, The Journal of pediatrics.

[3]  W. Kiess,et al.  Development of a Highly Sensitive Nonisotopic Immunoassay for the Determination of Salivary 17-Hydroxyprogesterone: Reference Ranges throughout Childhood and Adolescence , 1998, Pediatric Research.

[4]  L. Ibáñez,et al.  Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. , 1997, Pediatrics.

[5]  I. Silva,et al.  Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia , 1997, Archives of disease in childhood.

[6]  D. Merke,et al.  New approaches to the treatment of congenital adrenal hyperplasia. , 1997, JAMA.

[7]  I. Hughes,et al.  Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience , 1997, Clinical endocrinology.

[8]  B. Hauffa,et al.  Treatment and Disease Effects on Short-term Growth and Adult Height in Children and Adolescents with 21-hydroxylase Deficiency , 1997, Klinische Padiatrie.

[9]  M. New,et al.  The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. , 1996, The Journal of clinical endocrinology and metabolism.

[10]  E. Espiner,et al.  Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. , 1995, The New Zealand medical journal.

[11]  D. Grant,et al.  Adult height in women with early‐treated congenital adrenal hyperplasia (21‐hydroxylase type): relation to body mass index in earlier childhood , 1995, Acta paediatrica.

[12]  J. Batch,et al.  Adrenal 21‐hydroxylase deficiency in childhood: 25 years' experience , 1995, Journal of paediatrics and child health.

[13]  M. Forest,et al.  [Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency]. , 1994, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[14]  W. Miller,et al.  Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency. , 1994, The Journal of clinical endocrinology and metabolism.

[15]  I. Hughes,et al.  Dexamethasone treatment for congenital adrenal hyperplasia. , 1990, Archives of disease in childhood.

[16]  I. Hughes,et al.  Growth and body proportions in congenital adrenal hyperplasia. , 1989, Archives of disease in childhood.

[17]  M. New,et al.  The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). , 1986 .

[18]  G. Clayton.  Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. , 1986, Acta endocrinologica. Supplementum.

[19]  J. Tanner,et al.  Clinical longitudinal standards for height and height velocity for North American children. , 1985, The Journal of pediatrics.

[20]  P. A. Lee,et al.  Adult height and fertility in men with congenital virilizing adrenal hyperplasia. , 1978, The New England journal of medicine.

[21]  J. Holcombe,et al.  The effect of therapy on mature height in congenital adrenal hyperplasia. , 1978, The Journal of clinical endocrinology and metabolism.

[22]  I. Ghali,et al.  LINEAR GROWTH AND PUBERTAL DEVELOPMENT IN TREATED CONGENITAL ADRENAL HYPERPLASIA DUE TO 21‐HYDROXYLASE DEFICIENCY , 1977 .

[23]  C. Migeon,et al.  Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. , 1977, The Journal of pediatrics.

[24]  A. Prader,et al.  Experience with long-term therapy in congenital adrenal hyperplasia. , 1974, The Journal of pediatrics.

[25]  A. Tenore,et al.  Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency). , 1997, Hormone research.

[26]  R. Voutilainen,et al.  Growth of Patients with 21-Hydroxylase Deficiency: An Analysis of the Factors Influencing Adult Height , 1997, Pediatric Research.

[27]  W. Miller,et al.  Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 1991, Advances in human genetics.

[28]  G. R. León,et al.  Hiperplasia adrenal congenita secundaria a deficiencia de 21-hidroxilasa , 1990 .

[29]  M. New,et al.  Growth and final height in classical and nonclassical 21-hydroxylase deficiency. , 1989, Journal of endocrinological investigation.